Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 3Terminated 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 3Head & Neck 2CNS 2Myeloid 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Colorectal Neoplasms 10Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Melanoma 2Lung Neoplasms 2Carcinoma, Renal Cell 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Unresectable Metastatic Colorectal Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Ras-mutated Metastatic Colorectal Cancer 1Prostatic Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Margins of Excision 1Kidney Neoplasms 1Histiocytosis 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Neoplasms 1

Interventions

pembrolizumab 115Carboplatin 103Pemetrexed 90Cisplatin 58Paclitaxel 47osimertinib 41Drug Therapy 40Nivolumab 39Docetaxel 35Specimen Handling 33Magnetic Resonance Spectroscopy 28Bevacizumab 26durvalumab 23Gemcitabine 22cemiplimab 21Radiotherapy 20130-nm albumin-bound paclitaxel 20Radiosurgery 19tislelizumab 18atezolizumab 17aflutinib 15Cetuximab 15Immunotherapy 14Immune Checkpoint Inhibitors 14Platinum Compounds 13Ipilimumab 13Biopsy 12Standard of Care 11Surgical Procedures, Operative 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Non-Small-Cell Lung × IFL protocol × Clear all
NCT06179160 2026-05-04

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Incyte Corporation

Phase 1 Recruiting
710 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡